12.50
-0.06 (-0.44%)
Previous Close | 12.55 |
Open | 12.45 |
Volume | 230,689 |
Avg. Volume (3M) | 590,534 |
Market Cap | 935,181,952 |
Price / Sales | 10.38 |
Price / Book | 2.75 |
52 Weeks Range | |
Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
Profit Margin | -121.73% |
Operating Margin (TTM) | -94.48% |
Diluted EPS (TTM) | -1.50 |
Quarterly Revenue Growth (YOY) | 170.30% |
Total Debt/Equity (MRQ) | 5.68% |
Current Ratio (MRQ) | 4.71 |
Operating Cash Flow (TTM) | -75.78 M |
Levered Free Cash Flow (TTM) | -21.20 M |
Return on Assets (TTM) | -13.89% |
Return on Equity (TTM) | -29.80% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Zymeworks Inc. | Bearish | Bearish |
AIStockmoo Score
Analyst Consensus | -2.0 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | 0.5 |
Average | -0.25 |
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Core |
% Held by Insiders | 0.19% |
% Held by Institutions | 103.29% |
Ownership
Name | Date | Shares Held |
---|---|---|
Redmile Group, Llc | 31 Mar 2025 | 4,788,945 |
Bnp Paribas Asset Management Holding S.A. | 31 Mar 2025 | 2,197,879 |
52 Weeks Range | ||
Median | 13.00 (4.04%) | |
Total | 1 Hold |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 03 Jul 2025 | 13.00 (4.04%) | Hold | 12.50 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |